|
1) Karakelides H, Sreekumaran Nair K. Sarcopenia of aging and its metabolic impact. Curr Top Dev Biol. 2005; 68: 123–48
|
|
|
|
2) Sakurai T, Iimuro S, Araki A, et al. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus. Gerontology. 2010; 56: 141-9
|
|
|
|
|
|
3) Multani AS, Chang S. WRN at telomeres: implications for aging and cancer. J Cell Sci. 2007; 120: 713-21
|
|
|
|
|
|
4) Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997; 91: 25–34
|
|
|
|
|
|
5) Yuan X, Ishibashi S, Hatakeyama S, et al. Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. Genes Cells. 1999; 4: 563-72
|
|
|
|
|
|
6) Mattson MP, Klapper W. Emerging roles for telomerase in neuronal development and apoptosis. J Neurosci Res. 2001; 63: 1-9
|
|
|
|
|
|
7) Caporaso GL, Chao MV. Telomerase and oligodendrocyte differentiation. J Neurobiol. 2001; 49: 224-34
|
|
|
|
|
|
8) Yano Y, Yoshida K, Osaki A, et al. Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues. Anticancer Res. 2002; 22: 4101-7
|
|
|
|
|
|
9) Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985; 43: 405-13
|
|
|
|
|
|
10) Greider CW. Telomere length regulation. Annu Rev Biochem. 1996; 65: 337-65
|
|
|
|
|
|
11) Weinstein BS, Ciszek D. The reserve-capacity hypothesis: evolutionary origins and modern implications of the trade-off between tumor-suppression and tissue-repair. Exp Gerontol. 2002; 37: 615-27
|
|
|
|
|
|
12) Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999; 97: 503-14
|
|
|
|
|
|
13) Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell. 2004; 14: 501-13
|
|
|
|
|
|
14) Hayflick L. Current theories of biological aging. Fed Proc. 1975; 34: 9-13
|
|
|
|
|
|
15) Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992; 89: 10114-8
|
|
|
|
|
|
16) Evans RJ, Wyllie FS, Wynford-Thomas D, et al. A P53-dependent, telomere-independent proliferative life span barrier in human astrocytes consistent with the molecular genetics of glioma development. Cancer Res. 2003; 63: 4854-61
|
|
|
|
|
|
17) Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell. 1987; 51: 887-98
|
|
|
|
|
|
18) Gardner, Shengxu Li, Sathanur R, et al. Rise in Insulin Resistance Is Associated With Escalated Telomere Attrition. Circulation. 2005; 111: 2171-7
|
|
|
|
|
|
19) Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Diabet Med. 2005; 22: 1151–6
|
|
|
|
|
|
20) Sampson MJ, Winterbone MS, Hughes JC, et al. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care. 2006; 29: 283–9
|
|
|
|
|
|
21) Minamino T, Orimo M, Shimizu I, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009; 15: 1082-7
|
|
|
|
|
|
22) Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752-61
|
|
|
|
|